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Abstract: The BCL-2 family is a challenging group of proteins to
target selectively due to sequence and structural homologies
across the family. Selective ligands for the BCL-2 family
regulators of apoptosis are useful as probes to understand cell
biology and apoptotic signalling pathways, and as starting
points for inhibitor design. We have used phage display to
isolate Affimer reagents (non-antibody-binding proteins based
on a conserved scaffold) to identify ligands for MCL-1, BCL-xL,
BCL-2, BAK and BAX, then used multiple biophysical character-
isation methods to probe the interactions. We established that
purified Affimers elicit selective recognition of their target BCL-
2 protein. For anti-apoptotic targets BCL-xL and MCL-1, com-
petitive inhibition of their canonical protein-protein interactions
is demonstrated. Co-crystal structures reveal an unprecedented
mode of molecular recognition; where a BH3 helix is normally
bound, flexible loops from the Affimer dock into the BH3
binding cleft. Moreover, the Affimers induce a change in the
target proteins towards a desirable drug-bound-like conforma-
tion. These proof-of-concept studies indicate that Affimers
could be used as alternative templates to inspire the design of
selective BCL-2 family modulators and more generally other
protein-protein interaction inhibitors.
Introduction
A central challenge in life sciences research is to identify
modulators of protein-protein interactions (PPIs).[1,2] Such mod-
ulators represent probes with which to uncover new under-
standing of structural and cellular biology, as well as starting
points for drug discovery. The BCL-2 family of PPIs are an
important class of α-helix-mediated interaction that control the
intrinsic apoptosis pathway.[3] Their critical role in apoptosis has
prompted efforts to identify modulators so as to facilitate
greater understanding of both BCL-2 family signalling and drug
discovery.[4–8] Moreover differing selectivities and specificities
amongst BCL-2 family member interactions[9,10] render the
family an outstanding model system to elaborate novel generic
chemical and biological approaches for protein-protein inter-
action modulation.[11,12] BCL-2 family proteins can be identified
through their BCL-homology (BH) domains and may be
categorised within three specific sub-groups (Figure 1a). Pro-
apoptotic (or executioner) proteins such as BAK and BAX
activate apoptosis through pore formation in the mitochondrial
membrane; anti-apoptotic proteins including BCL-2, MCL-1 and
BCL-xL, sequester pro-apoptotic members to prevent cell death;
and a group of regulatory proteins which bind to other BCL-2
members (including BIM, BID, BAD, NOXA and PUMA), mediate
initiation of apoptosis. In all cases binding between BCL-2
family members occurs through the BH3 homology domain of
one protein, which forms an α-helix upon binding and docks
into a complementary cleft on its partner (Figure 1b). The BH3
ligand exploits conserved hydrophobic residues in positions i, i
+4, i+7 and i+11 together with a conserved aspartic acid (at i
+9) to achieve high affinity interaction with the BH3 cleft
(Figure 1c). In silico and experimental approaches have been
used to identify selective sequences for individual BCL-2 family
members.[13–16] Multiple studies have endeavoured to identify
chemotypes which mimic the BH3 domains so as to orthosteri-
cally inhibit BCL-2/BH3 PPIs including: constrained
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peptides,[17–23] peptidomimetics,[24–27] small molecules[28–31] and
miniature proteins (identified with assistance from biological
selection).[32–33] In this work we have used a previously described
Affimer library[34–39] to identify ligands for MCL-1, BCL-xL, BCL-2,
BAK and BAX and selective inhibitors of MCL-1 and BCL-xL
interactions with cognate BH3 partners. Our aim was not only
to identify high affinity binders, but also to then screen for
subsets that would inhibit PPIs, provide multiple sequences for
motif identification, and to use those amenable to structural
studies to understand the mode of binding. Affimer reagents
belong to an emerging class of non-antibody-based protein
scaffolds which include, Monobodies, Darpins, Affibodies and
others,[40–44] which might offer advantages in therapeutic and
diagnostic settings associated with improved solubility, purifica-
tion, expression and stability. Affimer reagents are based on
either a human scaffold,[45] or a phytocystatin scaffold (Fig-
ure 1d) which has been optimised by homology.[39] Both show
high thermal stability and achieve molecular recognition
through one or two variable regions (VRs) of between six and
twelve amino acid residues. Multiple large libraries of Affimers
have been established permitting biological selection of
optimised binding reagents through randomisation within each
of the VRs.[39,46] These reagents provide access to distinct
compositional and conformational peptide diversity compared
to natural biological peptides, and can be identified via the
power of genetics rather than synthetic chemistry.
Results
Isolating affimers
Following expression using established methods (see the
Supporting Information), MCL-1, BCL-xL, BCL-2, BAK and BAX
were biotinylated and immobilised on plates, over which the
library of Affimers was panned in order to isolate high-affinity
binders (see the Supporting Information). Phage ELISA was then
used to identify clones that bind selectively for further analysis.
Following this screening, candidate Affimer reagents were
sequenced resulting in twelve unique sequences with affinity
for MCL-1 (from 24 clones), eleven for BCL-xL (21 clones), four
for BCL-2 (20 clones), five for BAX (31 clones) and four for BAK
(24 clones). Tables S1 and S2 in the Supporting Information
indicate the identified sequences and frequency.
Binding analysis of Affimers
Small-scale expression of the Affimers allowed preliminary
biophysical/biochemical analyses. For MCL-1 and BCL-xL, single
concentration fluorescence anisotropy (FA) competition assays
(Figure 2a, b) against BCL-xL/BODIPY-Ahx-BAK72–87 or MCL-1/
FITC-Ahx-mNOXA-B68–87 (using competitor Affimer at 1 μM) were
used to identify Affimers that inhibit cognate BH3 binding.
Inhibition was compared to positive controls BAK72–87 and ABT-
Figure 1. BCL-2 family structure and function. a) Schematic annotating the BCL-2 family member role in apoptosis. Activation of the executioner proteins
(purple) triggers apoptosis; this depends on the balance of anti-apoptotic proteins (green) vs. effectors (blue).[47–49] b) BCL-xL(green)/BIM(cyan) co-crystal
structure (PDB ID: 1PQ1) highlighting key residues for binding (pink for hydrophobic h1–h4 positions and key aspartic acid labelled above and below). c)
Sequences of BH3 modulators (key residues required for BH3 cleft affinity in dark red). d) Crystal structure of an Affimer highlighting variable regions (dark
grey) where amino acid variation is possible (PDB ID: 5A0O).[38]
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737 for BCL-xL and mNOXA-B68–87 for MCL-1 with the peptide
activity defined as 100% inhibition (ABT-737 is more active than
BAK therefore achieves 150% inhibition). From these assays,
three BCL-xL Affimers were identified with significant inhibitory
potency, (BCL-xL-AF6, BCL-xL-AF7 and BCL-xL-AF10) and two
MCL-1 Affimers (MCL-1-AF1 and MCL-1-AF11). It should be
noted that the screening process (for all of the BCL-2 family
targets), may have selected for Affimers that do not recognise
the BH3 cleft, so a degree of attrition is to be expected. We did
not have an established competition assay for BCL-2, BAK and
BAX. BAK, BAX and BCL-2 Affimers were therefore purified by
size-exclusion chromatography and confirmation of correct
Affimer folding was obtained through circular dichroism (CD,
see the Supporting Information, Figure S1). Binding ELISA using
a primary antibody for the His tag on the Affimer and secondary
HRP antibody established selective interaction between the
Affimer and BCL-2 targets (Figures 2 c, d and S2): BCL-2-AF1 to
BCL-2-AF3 and BAK-AF1 to BAK-AF4 were confirmed as genuine
binders, selective for their targets, but no BAX Affimers were
successfully confirmed from the ELISA analyses. This may arise
due to nonspecific and/or weak binding of Affimers towards
BAX. Ultimately, the competitive inhibitors of BCL-xL and MCL-1
identified from these preliminary screens were considered
sufficient for more detailed studies exploring the structural and
thermodynamic bases of molecular recognition.
Biophysical analysis of Affimers
Larger-scale expression in E. coli of the five Affimers identified
from single-point FA competition allowed the purified proteins
to be tested in full dose response fluorescence anisotropy
competition assays against their target (Figure 3a, b). BCL-xL-
AF10 showed problems during purification so was not further
characterised. Both BCL-xL-AF6 (IC50=448�53 nM) and BCL-xL-
AF7 (IC50=393 �54 nM) were shown to act as sub μM inhibitors
of the BCL-xL/BAK interaction (Figure 3a) but were ineffective in
inhibiting the MCL-1/NOXA  B interaction. Similarly, the Affimers
selected for MCL-1 binding were shown to act as low μM
inhibitors of their target interaction (MCL-1-AF1 IC50=2.1�
0.2 μM; MCL-1-AF11 IC50=3.2�0.4 μM) but did not inhibit BCL-
xL /BAK, (Figure 3b), demonstrating selectivity.
Isothermal titration calorimetry (ITC; Figures 3c, d and S3,
Table 1) confirmed the conclusions garnered from competition
FA and gave Kd values consistent with the determined IC50
values. Both BCL-xL-AF6 (BCL-xL selective) and MCL-1-AF11
(MCL-1 selective) Affimers exhibited favourable enthalpic but
Figure 2. Binding analysis and selectivity of BCL-2 family binding Affimers.
Single-point screening of a) BCL-xL binding Affimers (1 μM, n=3) for
competitive inhibition of BH3 binding and b) MCL-1 binding Affimers (1 μM,
n=3. Binding ELISA for c) BAK-AF4 and d) BCL-2-AF3. Error bars represent
SD.
Figure 3. Biophysical analyses of BCL-xL and MCL-1 binding Affimers.
Fluorescence anisotropy competition assays (n=3) for a) BCL-xL/BODIPY-
Ahx-BAK72–87 and b) MCL-1/FITC-Ahx-mNOXA-B68–87. ITC data for binding of
Affimers to BCL-xL and MCL-1, thermograms and curve fitting for ITC
analyses on the c) BCL-xL-AF7/BCL-xL and d) MCL-1-AF11/MCL-1 interactions;
colour coding as for (a).
Table 1. Thermodynamic parameters of Affimer/BCL-xL and Affimer/MCL-1
binding determined by ITC.
Protein Ligand Kd [nM] ΔH [kJ/mol] TΔS [J/mol]
BCL-xL BCL-xL-AF6 90.9�3.0   45.3�0.93   17.1
BCL-xL BCL-xL-AF7 38.6�1.0   26.5�0.75 53.0
MCL-1 MCL-1-AF11 3400�400   34.4�1.76   11.34
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unfavourable entropic contributions to binding (it was not
possible to obtain data for MCL-AF1). In the case of BCL-xL-AF6
a particularly strong enthalpic contribution was observed. On
the other hand BCL-xL-AF7 was found to be favourable in both
the enthalpic and entropic terms. Given the hydrophobic nature
of the BH3 binding cleft and high conservation of aliphatic side
chains at key positions in both BH3 sequences and the Affimers
(see discussion of co-crystal structure below), the observation
that different thermodynamic signatures can be employed to
achieve recognition could be a useful consideration in inform-
ing inhibitor design. Whilst thermodynamic signatures are
notoriously difficult to interpret, and enthalpically driven hydro-
phobic molecular recognition has been documented, the
“classical” view of hydrophobic driven binding is one of
entropic desolvation.[50–53] Moreover, our own prior studies
characterised BH3/BCL-2 family interactions as entropically
driven.[20]
Whilst the Affimer technology regularly produces binders
with Kd in the nanomolar range,
[36] here we added multiple
layers of screening (inhibition of BH3 binding; compatible with
anisotropy and ITC experiments) in addition to panning for high
affinity binders. This will naturally lead to an attrition rate where
clones that do not meet the criteria are lost, which may explain
the slightly lower affinities we observe (Table 1). In this study,
we chose this approach as the selectivity achieved here is of
significantly greater value than affinity alone in experiments
where inhibition of a single member of a highly homologous
family is desired. With additional and more stringent panning
and selection (potentially quicker), or a larger library or use of
affinity maturation techniques (slower), better affinities may be
achievable where all criteria are met.
Crystal structures and conformational selection
Having established that Affimers act as selective inhibitors of
BCL-2 family PPIs, we attempted to obtain co-crystals to allow
high-resolution structural interpretation of the interactions.
BCL-xL-AF6/BCL-xL, BCL-xL-AF7/BCL-xL and MCL-1-AF11/MCL-1
co-crystals were obtained (see the Supporting Information, and
Table S3); and the structures solved by molecular replacement
using Phaser.[54]
For BCL-xL-AF6/BCL-xL, the crystals diffracted to 1.91 Å, and
the asymmetric unit contains one domain swapped dimer of
BCL-xL, with one BCL-xL-AF6 bound to the cleft of each
monomer (Figure 4b, c). For BCL-xL-AF7/BCL-xL, the crystals
diffract to 2.24 Å, and the asymmetric unit contains two domain
swapped dimers of BCL-xL, with one BCL-xL-AF7 bound to the
cleft of each monomer (Figure 4b, d). The residues within the
VRs of both Affimers interact with residues lining the BH3-
binding cleft on the surface of BCL-xL. Representative electron
density is presented in Figure S4. As expected, given that we
selected for competitive Affimers, the Affimers bind at the BH3
binding groove. Indeed, the Affimers use some of the available
binding pockets in the groove. In BCL-xL-AF6, F43 binds to the
pocket as does F101 on BIM (in PDB 5C3G), and F76 binds the
same pocket as I97 on BIM. For BCL-xL-AF7, W41 binds the same
pocket as F101 on BIM. However, the universally conserved BH3
Asp which hydrogen-bonds to Arg on BCL2- family members is
not replicated in any way by the Affimer.
On inspection it is apparent that the Affimers select a
distinct conformation of the BCL-xL domain. The binding groove
on BCL-xL is formed by helices 3 and 4 (Figure 5) and helix 3 is
mobile such that the width of the groove can vary. When BH3
peptide is bound, helix 3 moves to accommodate the peptide
in a relatively wide groove (groove open conformation). By
comparison, when BCL-xL is bound to the small molecule ABT-
737, and other small molecules, such as WEHI-539 (Table S4),[55]
or to BCL-xL-AF6 and BCL-xL-AF7, the groove is narrower
(Figure 5). When bound to BAK peptide the groove is 14.8 Å
wide at the widest point (Figure 5a), whereas in the small
molecule and Affimer bound conformation it is ~11.0 Å wide
(Figure 5b and Table S4). All four copies of BCL-xL-AF7/BCL-xL in
the asymmetric unit have this narrow groove, that is, groove-
closed conformation, thus suggesting that this is independent
Figure 4. Affimer: BCL-xL co-crystal structures. a) Cartoon representation of
Bcl-xL bound to BAK peptide (PDB ID: 5FMK), in the same orientation in all
panels (the blue sphere is at the N terminus, red sphere C terminus). b)
Overlay of Affimers BCL-xL-AF6 (yellow) and BCL-xL-AF7 (brown) bound to
BCL-xL (green) illustrating the projection of Affimer loops into the BH3
binding cleft. c) Enlargement of hydrophobic clusters from VRs 1 and 2 of
BCL-xL-AF6 (magenta side chains, labelled) projecting into the BH3 cleft. d)
Hydrophobic cluster from VRs 1 and 2 of BCL-xL-AF7 (purple side chains,
labelled). Both Affimers bind in the cleft, but at slightly different sites and
using different side chains.
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of crystal packing. For clarity, an overlay of the BCL-xL domain
only, when in complex with BIM, Affimer and WEHI-539, is
presented in Figure S5. This suggests that not only are Affimers
selecting a single conformation from the multiple dynamic
possibilities in solution, but also that they could be used to
select a conformation that is desired by the experimenter. In
this case, not only does the Affimer bound conformation
correspond to a small molecule bound conformation (thus this
might conceptually be a better starting point for structure
based drug design), but the groove closed conformation is also
a conformation where the groove is too narrow to accommo-
date the BH3 helix, possibly potentiating the orthosteric
competitive effect.
For MCL-1-AF11/MCL-1, the crystals diffract to 2.20 Å, and
the asymmetric unit contains 4 copies of the complex (Fig-
ure 6a, b) with representative electron density in Figure S4.
Again, the competition with BH3 peptide is mediated by VR
residues inserted into the binding groove, with W73 of MCL-1-
AF11 binding in the same pocket as V85 of NOXA (PDB ID:
2NLA); unsurprisingly, all three crystal structures reveal that the
Affimers use the available pockets in the peptide binding site
for binding. Again, as for the BCL-xL Affimers, we observe that
the binding of Affimer selects a desirable conformation. Song
et al.[56] have shown that MCL-1 can adopt multiple conforma-
tions in solution with differing outcomes in the cell. When BIM
BH3 is bound, MCL-1 adopts a nonhelical conformation at the
QRN motif around Arg222. By contrast, when bound to Mule
BH3 or a range of small molecules, the QRN motif is helical
(Figure 6c). Critically, when the QRN motif is helical, then
ubiquitin can be added at this motif, and this promotes cellular
degradation by the proteasome. By both competitively inhibit-
ing BH3 binding at the groove, and promoting degradation in
cells, the small molecules dramatically reduce MCL-1 activity in
treated cells, promoting apoptosis in MCL-1 dependent cancer
cell lines. Interestingly, our structure shows that MCL-1-AF11
Figure 5. Conformational selection of BCL-xL by the Affimers. When bound
to Affimer (BCL-xL-AF6 or BCL-xL-AF7), BCL-xL is in the small-molecule-bound
conformation, not the peptide-bound conformation. a) Superposition of
BCL-xL when bound to BCL-xL-AF7 (BCL-xL dark green, BCL-xL-AF7 brown) vs.
BAK (PDB ID: 5FMK; BCL-xL blue, BAK peptide yellow) reveals a change in
conformation at the peptide binding groove (note the different position of
the helix towards the bottom of the panel). b) Superposition of BCL-xL when
bound to BCL-xL-AF7 (dark green) vs. WEHI-539 (PDB ID: 3ZLR; BCL-xL cyan,
compound in yellow) where the groove is in the same conformation (note
the overlay of the helices). The helix binding groove is 5 Å wider at the last
turn when bound to peptide than to WEHI-539 or BCL-xL-AF7 (14.8 vs. 10–
11 Å). This might be a favourable conformation to select for protein-protein
interaction inhibition.
Figure 6. The Affimer/MCL-1 co-crystal structure suggests conformational
selection. a) Affimer MCL-1-AF11 (brown) bound to MCL-1 (green) illustrating
projection of Affimer loops into the BH3 binding cleft. Overlaid on NOXA
(cyan)-bound MCL-1. b) Ubiquitylatable region of MCL-1 bound to BIM
(grey), Mule (yellow) and MCL-1-AF11 (brown). Note the position of the
arginine carbonyl group: Mule and Affimer select the desired ubiquitylatable,
degradable conformation, whereas BIM does not. c) Enlargement of hydro-
phobic clusters from VRs 1 and 2 (pink side chains, labelled) projecting into
the BH3 cleft.
ChemBioChem
Full Papers
doi.org/10.1002/cbic.202000585
5ChemBioChem 2020, 21, 1–10 www.chembiochem.org © 2020 The Authors. Published by Wiley-VCH GmbH
These are not the final page numbers! ��
Wiley VCH Montag, 02.11.2020
2099 / 183192 [S. 5/10] 1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
also selects the desired helical, ubiquitylatable, conformation
(Figure 6c), again demonstrating that an Affimer can be isolated
that selects a specific desired conformation. Future studies will
focus on exploring the ability of the Affimer to promote this
modification.
All known biological partners,[4] and indeed all designed
peptides thus far,[13,14, 57–59] that interact with BCL-2 family
proteins at the BH3 groove do so with peptide in a helical
conformation. Crucially, the VRs do not adopt an α-helical
conformation to make interactions with the BH3 binding cleft
(presumably in part because they are constrained from doing
so). Despite the absence of a helical binding conformation, the
Affimers project amino acids side chains so as to mimic key
hydrophobic and polar contacts made by BH3 ligands and BCL/
MCL. Thus, we have identified proteins that bind to the BH3
binding groove via a noncanonical fold. Peptidomimetics based
on this structure, rather than the canonical α-helices, may
therefore represent a novel starting point for small molecule
discovery.
Discussion
We have used the Affimer libraries to isolate reagents that are
highly selective for their targets and can discriminate between
related homologues such as BCL-2 family proteins. Comparison
between the Affimer/BCL-xL and BCL-xL/BIM (PDB ID: 1PQ1)
structures illuminates key features; the BH3 cleft narrows in
response to Affimer binding in contrast to the wider cleft
observed for binding of BIM (Figure 5a). The BCL-xL conforma-
tion in the Affimer bound form is much more similar to that
observed for small molecule bound structures such as WEHI-
539 (PDB ID: 3ZLR. Figure 5b), where BCL-xL is also domain
swapped.
Similarly, when comparing the structures of MCL-1 bound
to peptide versus Affimer we observe that the variable loops of
the Affimer are inserted into the BH3 binding groove and that a
desirable conformation is selected. In this case, the region
where the protein conformation is affected is remote from the
BH3 cleft, but again reflects a small molecule bound conforma-
tion. For BIM bound MCL-1, the conformation at QRN (around
Arg222) is nonhelical and not ubiquitylatable. In contrast, MCL-
1 bound to small molecules from Song et al.,[56] UMI-77,
Maritoclax and TW-37, or Affimer MCL-1-AF11, have a helical
conformation around the QRN motif. The helical QRN motif can
be ubiquitylated; BH3 ligands that promote this conformation
offer both orthosteric inhibition of BH3 binding and degrada-
tion by the proteasome to potentiate the removal of MCL-1
function in cells. The Affimer again selects a conformation of a
target protein to promote a desired functional outcome.
These data, and a previous report,[34] imply that Affimers can
be used not only to identify selective sequences that differ-
entiate between related family members, but also that they can
be used for conformational selection of productive or desirable
binding modes. The role of conformational selection in studies
of protein-protein interactions is increasingly being
recognised.[60–65] Still, it remains a major challenge to account
for protein dynamics in structure-based drug-design.[66] This
library of Affimers allows exploration of a dynamic range of
protein target conformers, potentially facilitating generation of
template pharmacophores for small-molecule ligand design
and structure based-ligand design, which may offer an advant-
age over the current process that typically operates using static
crystal structures.[66]
Conclusion
In summary, we have identified unnatural protein ligands that
exhibit selectivity for different BCL-2 family members. Although
computational protein design has been applied to discovery of
BCL-2 family selective binders,[67] to our knowledge non-anti-
body based binding proteins have not previously been shown
to differentiate between these proteins, specifically BCL-xL and
MCL-1; this is noteworthy given the role of MCL-1 in driving
several cancers.[68,69] We note the attrition rate that is a
consequence of applying a variety of activity criteria as we
progressed along this pipeline. Of the 12 MCL-1 and 11 BCL-xL
binders identified, not all were inhibitors of the cognate BH3
binding, not all were amenable to biophysical assays, and only
three yielded high resolution crystal structures. This serves as a
reminder that a large number of binders is required in order to
identify ligands with multiple selection criteria applied.
The co-crystal structures provide inspiration for the struc-
ture-based design of peptide and small molecule based BCL-2
family modulators. Similarly, BCL-2 binding Affimers themselves
could be elaborated for therapeutic or diagnostic use;[34,70] goals
we will pursue in due course. Of more generic significance is
the observation that noncanonical folds can substitute for
native folds in peptide/protein based inhibitors of PPIs;[71,72] this
is reminiscent of the use of a β-hairpin to mimic an α-helix for
p53/hDM2 inhibition.[73-74] In contrast to those studies, the
sequences identified here were obtained under selection
pressure, and this poses the question: to date BCL-2 family
proteins have only been observed to function in cells through
the canonical α-helix/cleft motif; are there biological modula-
tors of the BCL-2 family that act through other molecular modes
of interaction yet to be discovered?
Experimental Section
For BCL-2 family protein expression, biochemical/biophysical
screening and details of the crystallography, see the Supporting
Information.
Screening for Affimers BCL-2 family proteins were biotinylated by
using EZ-link NHS-SS-biotin (Pierce), according to the manufac-
turer’s instructions. Biotinylation was confirmed using streptavidin
conjugated to horseradish peroxidase (HRP). Biotin-BCL-2 family
proteins were added and incubated on pre-blocked streptavdin
plate, the plate was then washed using a KingFisher robotic
platform (ThermoFisher) and 1012 cfu of the prepanned phage
library was added and incubated for 2.5 h with shaking. Wells were
washed ten times and eluted with 100 μL 0.2 M glycine (pH 2.2) for
10 min, neutralised with 15 μL 1 M Tris·HCl (pH 9.1), further eluted
with triethylamine 100 mM for 6 min, and neutralised with 1 M
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Tris·HCl (pH 7). Eluted phage were used to infect ER2738 cells for
1 h at 37 °C and 90 rpm then plated onto LB agar plates with
100 μg/mL carbenicillin and grown overnight. All colonies were
scrapped into 5 mL of 2XYT with carbenicillin (10 μg/mL) and 1×
109 M13 K07 helper phage were added. After an overnight
incubation phage were precipitated with 4% poly(ethylene glycol)
8000, 0.3 M NaCl and resuspended in 1 mL of 10 mM Tris, pH 8.0,
1 mM EDTA (TE buffer). 2 μL phage suspension was used for the
second round panning round using streptavidin magnetic beads as
opposed to streptavidin plates (Invitrogen); otherwise the second
pan was conducted in the same way as the first pan. The third pan
was conducting using neutravidin high binding capacity plates
(Pierce). After the final pan colonies were picked, an ELISA was
conducted to select positive clones (in the same way as the
enrichment ELISA) which were sent for Sanger sequencing.
Overexpression and purification of Affimers The Affimers were
subcloned from the phage display vector into pET11a then
expressed and purified from E. coli strain Rosetta 2. 10 mL of
overnight starter culture was used to inoculate 1 L 2×YT containing
125 μg/mL Ampicillin Cultures were grown at 37 °C to an OD600 of
0.6–0.8, the temperature was then switched to 18 °C, and protein
expression was induced by the addition of 0.5 mM IPTG. Induced
cultures were grown at 18 °C overnight before harvesting by
centrifugation (Beckman JLS 8.100 rotor, 4500 rpm, 12 min, 4 °C).
Cells were resuspended in 50 mM Tris (pH 8.0), 500 mM NaCl,
15 mM imidazole and lysed by sonication in the presence of 10 μL
of 1 U.mL-1 DNase I per litre of over-expression culture and cell
lysate was clarified (Beckman JA25.50 rotor, 17000 rpm, 45 min,
4 °C). The supernatant was filtered (0.45 μM syringe filter) before
application onto a 5 mL HisTrap that had previously been
equilibrated with 50 mM Tris pH 8.0, 500 mM NaCl, 15 mM
imidazole. The cleared cell lysate was then allowed to flow through
the HisTrap with the aid of a peristaltic pump. The HisTrap was
then washed with 10 CV of 50 mM Tris pH 8.0, 500 mM NaCl,
15 mM imidazole followed by 10 CV 50 mM Tris pH 8.0, 500 mM
NaCl, 50 mM imidazole and 10 CV 50 mM Tris pH 8.0, 500 mM NaCl,
100 mM imidazole. The Affimer was then eluted from the HisTrap
with 50 mM Tris pH 8.0, 500 mM NaCl, 300 mM imidazole. Success-
ful elution was confirmed on a gel before further purification was
undertaken. The eluted Affimer was concentrated (Amicon Ultra
centrifugal filter, MWCO 10000) to approximately 5 mL. The sample
was then filtered before being loaded onto a Superdex 75 column
(GE healthcare) equilibrated in 50 mM Tris (pH 8.0), 250 mM NaCl,
0.5 mM DTT, 2.5% Glycerol. The protein eluted as a monomer from
gel filtration. The purified protein was concentrated to ~6 mg/mL
and stored at   80 °C with the addition of 5% glycerol.
Additionally, Affimers BCL-xL-AF6 and MCL-1-AF11 were subcloned
into pET28a His-SUMO expression vector to remove flexible
residues at the N and C-termini which have hindered crystallisation.
The constructs were over-expressed in the E. coli strain Rosetta 2.
10 mL of overnight starter culture was used to inoculate 1 L 2 ×YT
containing 50 μg/mL kanamycin. Cultures were grown at 37 °C to
an OD600 of 0.6–0.8, the temperature was then switched to 18 °C,
and protein expression was induced by the addition of 0.5 μM IPTG.
Induced cultures were grown at 18 °C overnight before harvesting
by centrifugation (Beckman JLS 8.100 rotor, 4500 rpm, 12 min,
4 °C). Cells were re-suspended in 20 mM Tris pH 8.0, 500 mM NaCl,
15 mM imidazole and lysed by sonication and cell lysate was
clarified (Sorvall SS34 rotor, 17000 rpm, 45 min, 4 °C). The super-
natant was filtered (0.45 μM syringe filter) before application onto a
5 mL HisTrap that had previously been equilibrated with 20 mM
Tris pH 8.0, 500 mM NaCl, 15 mM imidazole. The HisTrap was then
washed with 10 CV of 50 mM Tris pH 8.0, 500 mM NaCl, 15 mM
imidazole followed by 10 CV 50 mM Tris pH 8.0, 500 mM NaCl,
50 mM imidazole. The His-SUMO-Affimer fusion protein was then
eluted from the HisTrap with 20 mM Tris pH 8.0, 500 mM NaCl,
300 mM imidazole. The His-SUMO-Affimer fusion protein was
cleaved overnight in dialysis into 20 mM Tris pH 8.0, 250 mM NaCl
in the presence of Smt3 protease, Ulp1, overnight at 4 °C. To
remove any uncleaved Affimer, His-SUMO and Ulp1, the sample
was reapplied to a HisTrap in 20 mM Tris pH 8.0, 250 mM NaCl and
the flow through containing Affimer collected. This was concen-
trated (Amicon Ultra centrifugal filter, MWCO 10000) to approx-
imately 10 mL. The sample was then filtered before being loaded
onto a Superdex 75 column (GE healthcare) equilibrated in 20 mM
Tris (pH 8.0), 250 mM NaCl, 0.5 mM DTT, 2.5% glycerol. The protein
eluted as a monomer from gel filtration. The purified protein was
concentrated to ~6 mg/mL and stored at   80 °C with the addition
of 5% glycerol.
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Affimer reagents (non-antibody
binding proteins) are identified that
bind selectively to the anti-apoptotic
proteins BCL-xL and MCL-1. Crystallo-
graphic studies reveal an unprece-
dented mode of molecular recogni-
tion in which flexible loops from the
Affimer dock into the BH3 binding
cleft as opposed to a canonical α-
helix. Furthermore the Affimers
induce changes in the target
proteins towards desirable drug-
bound-like conformations.
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